{
  "id": "mhgap#risk_safety_eabb355a",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "in 58 3. Recommendations (common in LMICs) may interfere with continuation characteristics (e.g. higher risks and side-effects of treatment. that may be associated with pregnancy or older y Generic TCAs and many generic SSRIs are associated age), side-effects profiles (e.g. sexual dysfunction, with low acquisition costs. Cost of daily dose of sleep problems, weight gain) and availability (e.g. generic antidepressants varies from region to region continuous availability, costs). throughout the world ranging between 3% and 9% y Explain rationale for prescribing and provide written of minimum wage (131). and verbal information on benefits and harms, y For the treatment of depressive disorder, the WHO side-effects, drug interactions, the importance EML (13) includes: of taking medicines as prescribed and the likely – TCA: amitriptyline; time to improvement in symptoms. – SSRI: fluoxetine (therapeutic alternatives: y Regularly review the effectiveness of the medicine citalopram, escitalopram, fluvoxamine, and side-effects with the person during the first paroxetine and sertraline). three months of treatment and every three months afterwards. For adults who experience side-effects y The Interagency health kit 2017 includes fluoxetine after starting medicine, consider closer monitoring (133). of their symptoms, reducing the dose of the y Specific types of antidepressants selected should medicine or stopping the medicine gradually and carefully consider factors such as demographic offering alternative interventions. DEP2. How long should treatment with antidepressants continue in adults with depressive episode/disorder? Recommendation (update): In adults with moderate-to-severe depression who have benefited from initial antidepressant treatment, continuation of the antidepressant treatment should be considered for at least six months after remission. Treatment should be regularly monitored, with special attention to treatment adherence, change in depressive symptoms and possible adverse effects. Strength of recommendation: Conditional Certainty of evidence: Very low Justification average of relapse-free months over a year was y Two meta-analyses contributed to the evidence higher in the pharmacotherapy groups than in the profile: Kato et al., 2021 (40 RCTs) (134); Zhou et al., placebo groups. 2022 (40 RCTs) (135). One primary study (RCT) also y The certainty of evidence for the mean difference contributed: Lewis et al., 2021 (136). in relapse rates between antidepressant medicines y Most of the difference in relapse rates (85.5%) and pill placebo from 0 to 9 months, and relapse- between pharmacotherapy and placebo occurred in free months at one year post-remission, response or the first three months (63.9%) and first six months recovery, is very low. (another 22.6%). The difference in relapse-free rates y The certainty of evidence is low for relapse rates at becomes much smaller after six months. six months post-remission between antidepressants y The relapse rate at one year was lower for and pill placebo. pharmacotherapy compared with placebo. The 59",
  "gloss_vi": "In 58 3. recommendations (common in lmics) may interfere with continuation characteristics (e.g.",
  "source": "WHO mhGAP-IG 2023",
  "url": "https://www.who.int/",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety",
      "screening_cues",
      "management"
    ],
    "life_topics": [
      "sleep",
      "study"
    ],
    "advice_section": [],
    "audience": [],
    "risk_band": "low"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn in 58 3. Recommendations (common in LMICs) may interfere with continuation characteristics (e.g. higher risks and side-effects of treatment. that may be associated with pregnancy or older y Generic TCAs and many generic SSRIs are associated age), side-effects profiles (e.g. sexual dysfunction, with low acquisition costs. Cost of daily dose of sleep problems, weight gain) and availability (e.g. generic antidepressants varies from region to region continuous availability, costs). throughout the world ranging between 3% and 9% y Explain rationale for prescribing and provide written of minimum wage (131). and verbal information on benefits and harms, y For the treatment of depressive disorder, the WHO side-effects, drug interactions, the importance EML (13) includes: of taking medicines as prescribed and the likely – TCA: amitriptyline; time to improvement in symptoms. – SSRI: fluoxetine (therapeutic alternatives: y Regularly review the effectiveness of the medicine citalopram, escitalopram, fluvoxamine, and side-effects with the person during the first paroxetine and sertraline). three months of treatment and every three months afterwards. For adults who experience side-effects y The Interagency health kit 2017 includes fluoxetine after starting medicine, consider closer monitoring (133). of their symptoms, reducing the dose of the y Specific types of antidepressants selected should medicine or stopping the medicine gradually and carefully consider factors such as demographic offering alternative interventions. DEP2. How long should treatment with antidepressants continue in adults with depressive episode/disorder? Recommendation (update): In adults with moderate-to-severe depression who have benefited from initial antidepressant treatment, continuation of the antidepressant treatment should be considered for at least six months after remission. Treatment should be regularly monitored, with special attention to treatment adherence, change in depressive symptoms and possible adverse effects. Strength of recommendation: Conditional Certainty of evidence: Very low Justification average of relapse-free months over a year was y Two meta-analyses contributed to the evidence higher in the pharmacotherapy groups than in the profile: Kato et al., 2021 (40 RCTs) (134); Zhou et al., placebo groups. 2022 (40 RCTs) (135). One primary study (RCT) also y The certainty of evidence for the mean difference contributed: Lewis et al., 2021 (136). in relapse rates between antidepressant medicines y Most of the difference in relapse rates (85.5%) and pill placebo from 0 to 9 months, and relapse- between pharmacotherapy and placebo occurred in free months at one year post-remission, response or the first three months (63.9%) and first six months recovery, is very low. (another 22.6%). The difference in relapse-free rates y The certainty of evidence is low for relapse rates at becomes much smaller after six months. six months post-remission between antidepressants y The relapse rate at one year was lower for and pill placebo. pharmacotherapy compared with placebo. The 59 In 58 3. recommendations (common in lmics) may interfere with continuation characteristics (e.g."
}